SEC Form SC 13G/A filed by Pulmonx Corporation (Amendment)

2/13/24 3:42:20 PM ET

Medical/Dental Instruments

Health Care

Get the next $LUNG alert in real time by email

SC 13G/A 1 LUNG_123123.txt CHAMPLAIN 13G TICKER LUNG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ________)* Pulmonx Corp (Name of Issuer) COMMON STOCK (Title of Class of Securities) 745848101 (CUSIP Number) 12/31/2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. 13G CUSIP No. 745848101 1. Names of Reporting Persons. Champlain Investment Partners, LLC 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) [ ] (b) [ ] 3. SEC Use Only 4. Source of Funds (See Instructions) 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) [ ] 6. Citizenship or Place of Organization Vermont Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 0 8. Shared Voting Power 9. Sole Dispositive Power 0 10. Shared Dispositive Power 11. Aggregate Amount Beneficially Owned by Each Reporting Person 0 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) [ ] 13. Percent of Class Represented by Amount in Row (11) 0.00% 14. Type of Reporting Person (See Instructions) IA 13G CUSIP No. 745848101 ITEM 1. (a) Name of Issuer: Pulmonx Corp (b) Address of Issuer's Principal Executive Offices: 700 CHESAPEAKE DRIVE REDWOOD CITY, CALIFORNIA 94063 ITEM 2. (a) Name of Person Filing: Champlain Investment Partners, LLC (b) Address of Principal Business Office, or if None, Residence: 180 Battery St., Burlington, Vermont 05401 (c) Citizenship: Vermont (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 745848101 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) [_] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [_] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [_] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a- 8). (e) [x] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G); (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a- 3); (j) [_] Group, in accordance with ss.240.13d- 1(b)(1)(ii)(J). ITEM 4. OWNERSHIP. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 0 (b) Percent of class: 0.00% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of INSTRUCTION. For computations regarding securities which represent a right to acquire an underlying security SEE ss.240.13d3(d)(1). ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. INSTRUCTION: Dissolution of a group requires a response to this item. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY. If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP. If a group has filed this schedule pursuant to ss.240.13d- 1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group. ITEM 9. NOTICE OF DISSOLUTION OF GROUP. Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. ITEM 10. CERTIFICATIONS. (a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b): "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect." (b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c): "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect." SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: 2/13/2024 Signature: Matthew Garcia Name/Title: Matthew Garcia / Chief Compliance Officer The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties for whom copies are to be sent. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

Get the next $LUNG alert in real time by email

Recent Analyst Ratings for

$LUNG

Date	Price Target	Rating	Analyst
6/4/2024	$12.00	Buy	Lake Street
2/23/2024	$16.00 → $14.00	Overweight → Equal Weight	Wells Fargo
9/5/2023	$18.00	Buy	Craig Hallum
2/27/2023	$10.00 → $15.00	Equal Weight → Overweight	Wells Fargo
1/3/2023	$8.00	Neutral → Underperform	BofA Securities
12/12/2022	$14.00 → $10.00	Neutral → Buy	Citigroup
7/11/2022	$23.00 → $19.00	Buy → Neutral	Citigroup
3/2/2022	$28.00	Neutral	BofA Securities

More analyst ratings

SEC Form SC 13G/A filed by Pulmonx Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for $LUNG

$LUNG Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

$LUNG Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

$LUNG SEC Filings

$LUNG Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SEC Form 10-Q filed by Pulmonx Corporation

Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Pulmonx Corporation

Lake Street initiated coverage on Pulmonx with a new price target

Pulmonx downgraded by Wells Fargo with a new price target

Craig Hallum initiated coverage on Pulmonx with a new price target

$LUNG Press Releases

Fastest customizable press release news feed in the world

Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference

Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Pulmonx to Present at the Stifel 2024 Healthcare Conference

$LUNG Market Insights

Live Market Insights

Lake Street Initiates Coverage On Pulmonx with Buy Rating, Announces Price Target of $12

Canaccord Genuity Maintains Buy on Pulmonx, Lowers Price Target to $15

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

$LUNG Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director French Glendon E. Iii sold $130,400 worth of shares (20,000 units at $6.52), decreasing direct ownership by 2% to 1,091,974 units (SEC Form 4)

Director French Glendon E. Iii sold $161,800 worth of shares (20,000 units at $8.09), decreasing direct ownership by 2% to 1,111,974 units (SEC Form 4)

CHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $30,721 worth of shares (4,586 units at $6.70), decreasing direct ownership by 2% to 295,433 units (SEC Form 4)

$LUNG Leadership Updates

Live Leadership Updates

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

$LUNG Financials

Live finance-specific insights

Pulmonx Reports Third Quarter 2024 Financial Results

Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024

Pulmonx Reports Second Quarter 2024 Financial Results

Recent Analyst Ratings for
$LUNG

$LUNG
Insider Purchases

$LUNG
Large Ownership Changes

$LUNG
SEC Filings

$LUNG
Analyst Ratings

$LUNG
Press Releases

$LUNG
Market Insights

$LUNG
Insider Trading

$LUNG
Leadership Updates

$LUNG
Financials